Novartis acquires Amblyotech

Novartis has acquired Amblyotech, a digital therapeutics company, for an undisclosed amount, with the hopes of developing a modality to combat lazy eye.

“By offering a noninvasive solution that has the potential to be significantly faster than current standards of care such as patching for children and adults impacted by lazy eye, Amblyotech’s software is a great example of how we can reimagine medicine using digital technology”

Nikos Tripodis, head of Novartis’ global ophthalmology business

Novartis plans to work with Ubisoft and McGill University to treat amblyopia (lazy eye), which affects around 3% of the world’s population and can potentially lead to a loss in vision.